DBV Technologies S.A. (DBVT) – What Are Researchers Thinking About This Stock?

DBV Technologies S.A. (NASDAQ:DBVT) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $45.25.

DBVT has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DBV Technologies in a research report on Thursday, October 15th. Citizens Jmp decreased their price objective on DBV Technologies from $55.00 to $47.00 and set a “market outperform” rating for the company in a report on Thursday, October 29th. Citigroup restated a “market outperform” rating on shares of DBV Technologies in a research note on Thursday, October 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of DBV Technologies in a report on Thursday, September 10th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a report on Friday, October 30th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. raised its position in shares of DBV Technologies by 170.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 21,600 shares of the company’s stock worth $249,000 after buying an additional 13,600 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in DBV Technologies during the third quarter valued at approximately $144,000. Perceptive Advisors LLC bought a new stake in DBV Technologies during the first quarter valued at approximately $20,146,000. Vivo Capital LLC grew its stake in DBV Technologies by 8.4% in the 1st quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock worth $55,726,000 after buying an additional 205,943 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new position in DBV Technologies in the 1st quarter worth approximately $21,159,000. 71.74% of the stock is owned by institutional investors.

DBV Technologies Stock Performance

Shares of DBVT stock opened at $11.02 on Monday. The firm has a market cap of $692.92 million, a price-to-earnings ratio of -3.66 and a beta of -0.84. DBV Technologies has a 52 week low of $8.63 and a 52 week high of $26.18. The firm’s 50-day simple moving average is $10.84 and its two-hundred day simple moving average is $16.40.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Wednesday, October 28th. The company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.41). DBV Technologies had a negative net margin of 5,392.17% and a negative return on equity of 120.95%. The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $0.56 million. Analysts forecast that DBV Technologies will post -2.22 earnings per share for the current year.

About DBV Technologies

DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. Founded in France, the company’s research centers on epicutaneous immunotherapy, an approach that delivers small amounts of an allergen through the skin using a patch. Its lead investigational program is Viaskin Peanut, a patch-based treatment being developed for peanut allergy. DBV has also conducted research into treatments for other conditions, including milk allergy and eosinophilic esophagitis.